

The United States Pharmacopoeia (USP) and the European Pharmacopoeia (EP) permit a degree of adjustment of HPLC parameters such as column size, mobile phase condition etc. if it is satisfying the requirements of system suitability. Allowable adjustment parameters are described in General Chapter <621> Chromatography of USP 41 and General Chapter 2.2.46 Chromatographic separation techniques of EP 9 each. Although both Pharmacopoeias permit to modify parameters, the allowable adjustments range may be different. For example, it is possible to modify the column size under the gradient condition in EP, but not allowed in USP. Modifying these analytical parameters within range is expected to reduce the analysis time.

This Technical Note introduces an example of analysis of Levocetirizine Dihydrochloride Tablets -ORGANIC IMPURITIES- in accordance with the USP. And an example of analysis that can be completed in a shorter analysis time after modifying the condition which is based on the USP General Chapter <621> Chromatography.

(K. Kanno)

### Allowable adjustments range in USP

According to the USP General Chapter <621> Chromatography, it is possible to modify the specific parameters as below tables if it is satisfying the requirements of system suitability.

#### -Allowable adjustments range of HPLC column parameters

	Isocratic	Gradient
Stationary Phase	Not allowed	
Particle size (dp, mm)	<b>L/dp ratio constant or Theoretical plate number : -25 to + 50%</b>	Not allowed
Length (L, mm)		
Inner diameter (dc, mm)	<b>Can be adjusted if the linear velocity is kept constant.</b>	

#### -Allowable adjustments range of HPLC system parameters

	Isocratic	Gradient
Flow rate (F, mL/min)	<b>Flow rate changes for both a change in column diameter and particle size can be made by:</b> $F_2 = F_1 \times [(dc_2^2 \times dp_1)/(dc_1^2 \times dp_2)]$ <b>Additionally, F<sub>2</sub> can be adjusted by ±50%</b>	Not allowed
Injection Vol.	<b>Can be adjusted as far as it is consistent with accepted precision, linearity, and detection limits.</b>	
Temperature	±10 °C	
Wavelength of UV	Not allowed	

F<sub>1</sub> Original Flow rate, μL/min  
F<sub>2</sub> Modified Flow rate, μL/min  
dp<sub>1</sub> Original Particle size, mm  
dp<sub>2</sub> Modified Particle size, mm  
dc<sub>1</sub> Original Inner Diameter, mm  
dc<sub>2</sub> Modified Inner Diameter, mm

#### -Allowable adjustments range of mobile phase parameters

	Isocratic/Gradient
pH	±0.2
Concentration of Salts in Buffer	<b>Within ±10 % if the permitted pH variation</b>
Ratio of Components	<b>The amounts of minor components (specified at 50 % or less) can be adjusted by ±30 % relative. However, the change in any component cannot exceed ±10 % absolute.</b>

The above tables are based on the USP41 NF36 General Chapter <621> Chromatography.

**Example: USP Levocetirizine Dihydrochloride Tablets – ORGANIC IMPURITIES**

This is an example of analysis of Levocetirizine Dihydrochloride Tablets -ORGANIC IMPURITIES- in accordance with the USP General Chapter <621> Chromatography. The USP specified condition were modified in the following procedure, and the modified condition for fast analysis were completed. USP specifies a 150 mm Length (L) × 4.6 mm Inner diameter (dp); 5 µm Particle size (dc) column operated at 1.0 mL/min. So L/dp is 50,000 and this value remains into the range between – 25 % to +50 % as below.

$$37,500 \leq L/dp \leq 75,000$$

The table below is an example of column size within the above L/dp range.

Length (L, mm)	I.D. (dc, mm)	Particle size (dp, µm)	Relative Values	
			L/dP	Flow rate (F, mL/min)
250	4.6	5	50,000	1.0
150	4.6	3	50,000	1.7
150	3.0	3	50,000	0.7
150	2.1	3	50,000	0.3
125	3.0	3	41,700	0.7
100	4.6	2	50,000	2.5
100	3.0	2	50,000	1.1
100	2.1	2	50,000	0.5
75	3.0	2	37,500	1.1

As shown in the above table, you can select from multiple column sizes for modifying the method. The column is selected the most suitable one depending on the column line up and HPLC instrument condition such as maximum pressure. This time, the column shown below table was selected for fast analysis.

	USP Specified condition	Allowable adjustments range	Modified condition
Length (L, mm)	250 mm	In case of 3 µm L: 113-225 mm	150 mm
Particle size(dp, µm)	5 µm		3 µm
L/dp	50,000		50,000
I.D. (dc, mm) Flow rate (F, mL/min)	4.6 mm 1.0 mL/min	In case of 3.0 mm I.D. F: 0.35-1.06 mL/min	3.0 mm 1.0 mL/min

**-Chromatograms-**

The retention time of USP specified condition is about 23 minutes. On the other hand, the retention time of modified condition is about 5.75 minutes and the analysis time was reduced about 75 %.

The analysis time of this application will be longer because the USP levocetirizine tablets organic impurity test specifies that analysis is performed 2.3 times the retention time of levocetirizine.


Furthermore, this analysis takes a long time to equilibrate the column because it uses unmodified silica-gel as HILIC mode. It is recommended to flow the mobile phase more than 30 times of empty column volume for column equilibration.

Therefore, the time of analysis and equilibration are reduced by modifying the condition and using smaller size column.

1. Levocetirizine (0.2 mg/mL)
2. Chlorobenzhydryl Piperazine (0.2 µg/mL)

### USP Specified HPLC Condition


**Column** : Inertsil SIL-100A  
 (5 µm, 250 x 4.6 mm I.D.)  
**Cat. No.** : 5020-01712  
**Mobile phase** : CH<sub>3</sub>CN/H<sub>2</sub>O/1M H<sub>2</sub>SO<sub>4</sub> in H<sub>2</sub>O  
 =93/6.6/0.4, v/v/v  
**Flow rate** : 1.0 mL/min  
**Temperature** : 30 °C  
**Detection** : UV 230 nm  
**Injection Vol.** : 20 mL



**Fast analysis and High-Throughput**

### Modified HPLC Condition

**Column** : Inertsil SIL-100A  
 (3 µm, 150 x 3.0 mm I.D.)  
**Cat. No.** : 5020-04225  
**Mobile phase** : CH<sub>3</sub>CN/H<sub>2</sub>O/1M H<sub>2</sub>SO<sub>4</sub> in H<sub>2</sub>O  
 =93/6.6/0.4, v/v/v  
**Flow rate** : **1.0 mL/min**  
**Temperature** : 30 °C  
**Detection** : UV 230 nm  
**Injection Vol.** : **10 mL**




### - Result of System Suitability Test

The results of the USP Specified method and the Modified method for fast analysis are shown in the table as below. These results are clearly satisfied that all of the system suitability requirements.

		Criteria	USP Specified method		Modified method for Fast analysis	
Resolution between peak1 and peak2		Not less than 3	11.7	PASS	7.31	PASS
Tailing factor of peak 1		Not more than 2	1.21	PASS	1.28	PASS
RSD%	Peak 1	Less than 1.0 %	0.18 %	PASS	0.05 %	PASS
	Peak 2	Less than 5.0 %	2.11 %	PASS	0.89 %	PASS

In generally, we select a smaller particle size column when modifying the method for fast analysis. Therefore, it is the most important to modify condition using the columns that have same separation pattern between different particle sizes.

Even with the use of same name column, separation patterns may change between different particle sizes. One of the reasons may be that the quality of bare silica-gels are difference with between particle sizes. GL Sciences has been synthesizing base silica-gels. So we can recommend the LC column of Inertsil / InertSustain series for modifying method analysis between the different particle sizes such as USP.



## HPLC Column

Cat.No. 5020—01712  
Cat.No. 5020—04225

Inertsil SIL-100A 5 μm, 250 × 4.6 mm I.D.  
Inertsil SIL-100A 3 μm, 150 × 3.0 mm I.D.

Shipping solvent of Inertsil SIL-100A is n-Hexane/Ethanol. At first, sufficient flashing with Ethanol is required before flowing with the mobile phase of Levocetirizine analysis due to the mobile phase is Acetonitrile/Water. It is recommended to flow the mobile phase more than 30 times of empty column volume for column equilibration.

-Empty column volume-  
250 × 4.6 mm I.D. : Approx. 4.2 mL  
150 × 3.0 mm I.D. : Approx. 1.1 mL

GL Sciences disclaims any and all responsibility for any injury or damage which may be caused by this data directly or indirectly. We reserve the right to amend this information or data at any time and without any prior announcement.

**GL Sciences Inc. Japan**  
22-1 Nishishinjuku 6-chome  
Shinjuku-ku, Tokyo  
163-1130, Japan

Phone: +81-3-5323-6620  
Fax: +81-3-5323-6621  
Email: [world@glsc.co.jp](mailto:world@glsc.co.jp)  
Web: [www.glsciences.com](http://www.glsciences.com)

**GL Sciences Inc. USA**  
4733 Torrance Blvd. Suite 255  
Torrance, CA 90503  
USA

Phone: +1-310-265-4424  
Fax: +1-310-265-4425  
Email: [info@glsciencesinc.com](mailto:info@glsciencesinc.com)  
Web: [www.glsciencesinc.com](http://www.glsciencesinc.com)

**GL Sciences B.V.**  
Dillenburgstraat 7C  
5652AM, Eindhoven  
The Netherlands

Phone: +31-40-254-9531  
Email: [info@glsciences.eu](mailto:info@glsciences.eu)  
Web: [www.glsciences.eu](http://www.glsciences.eu)

**GL Sciences (Shanghai) Limited**  
Tower B, Room 2003  
Far East International Plaza  
No.317 Xianxia Road, Changning District  
Shanghai, China 200051

Phone: +86-21-62782272  
Email: [contact@glsciences.com.cn](mailto:contact@glsciences.com.cn)  
Web: [www.glsciences.com.cn](http://www.glsciences.com.cn)



**International Distributors**

Visit our Website at [www.glsciences.com/distributors](http://www.glsciences.com/distributors)